VYNE Therapeutics to Participate in Leerink Partners Therapeutics Forum
Provided By GlobeNewswire
Last update: Jun 26, 2024
BRIDGEWATER, N.J., June 26, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced members of VYNE’s management will participate in one-on-one meetings at the Leerink Partners Therapeutics Forum on Immunology and Inflammation (I&I) and Metabolic Diseases on Tuesday, July 9, 2024.
1
0 (0%)
Find more stocks in the Stock Screener
VYNE Latest News and Analysis
5 days ago - ChartmillThese stocks are moving in today's pre-market sessionAs we await the opening of the US market on Wednesday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
